JW Therapeutics Acquires Syracuse Biopharma And License To Eureka Therapeutics Solid Tumor Technology In China

JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, announced the acquisition of Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries. Terms of the transaction were not disclosed. Dr. Cheng Liu, Founder and President of Eureka Therapeutics, will join the Board of Directors of JW Therapeutics, and Victor Shum, Chief Business Officer and General Counsel of Eureka, will join as a Board Observer. “We are excited to announce our acquisition of Syracuse, to expand our clinical development into solid tumor cancers,” said Dr. James Li, Co-Founder and CEO of JW Therapeutics. “Syracuse and Eureka have developed an elegant approach to treating solid tumors with their TCR-mimic and ARTEMIS® technologies. We’re looking forward to working with the team to bring the next generation of T cell immunotherapies to patients.” “We are excited that JW Therapeutics, the industry leader in cell immunotherapies in China, has recognized the value of our ARTEMIS® platform, and shares our passion and urgency for developing innovative immunotherapies for patients with cancer,” said Dr. Cheng Liu, Founder and CEO, Eureka Therapeutics. “With JW’s expertise, network and support, we hope to accelerate development of our T cell therapies against solid tumors. The incidence rate of HCC is very high in China, and JW is well positioned to use their broad expertise to develop these therapies and bring them to patients faster.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!